Brief survey on organometalated antibacterial drugs and metal-based materials with antibacterial activity.
Przemysław BiegańskiŁukasz SzczupakManuel ArrueboKonrad KowalskiPublished in: RSC chemical biology (2021)
Rising bacterial antibiotic resistance is a global threat. To deal with it, new antibacterial agents and antiseptic materials need to be developed. One alternative in this quest is the organometallic derivatization of well-established antibacterial drugs and also the fabrication of advanced metal-based materials having antibacterial properties. Metal-based agents and materials often show new modes of antimicrobial action which enable them to overcome drug resistance in pathogenic bacterial strains. This review summarizes recent (2017-2020) progress in the field of organometallic-derived antibacterial drugs and metal-based materials having antibacterial activity. Specifically, it covers organometallic derivatives of antibacterial drugs including β-lactams, ciprofloxacin, isoniazid, trimethoprim, sulfadoxine, sulfamethoxazole, and ethambutol as well as non-antibacterial drugs like metformin, phenformin and aspirin. Recent advances and reported clinical trials in the use of metal-based nanomaterials as antibiofouling coatings on medical devices, as photocatalytic agents in indoor air pollutant control, and also as photodynamic/photothermal antimicrobial agents are also summarized.
Keyphrases
- silver nanoparticles
- clinical trial
- anti inflammatory
- essential oil
- staphylococcus aureus
- escherichia coli
- low dose
- wound healing
- type diabetes
- cardiovascular disease
- pseudomonas aeruginosa
- air pollution
- cancer therapy
- cross sectional
- randomized controlled trial
- risk assessment
- cardiovascular events
- gold nanoparticles
- coronary artery disease
- mass spectrometry
- simultaneous determination
- high performance liquid chromatography
- anaerobic digestion
- phase iii
- anti inflammatory drugs
- visible light